Pure Global
NCT06372977

Kappa Index Versus Csf Oligoclonal Bands in Diagnosis of ms and Prediction of Disease Activity

Kappa Index Versus Csf Oligoclonal Bands in Diagnosis of Multiple Sclerosis and Prediction of Disease
Assiut University·ClinicalTrials.gov·diagnostic testNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Multiple Sclerosis
Drug/Device/Intervention
kappa index
Study type
Observational
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
Assiut University
Timeline & enrollment
Phase
N/A
Start date
May 01, 2024
End date
May 01, 2026
Enrollment
140 participants
Primary outcome

Assess the diagnostic performance of CSF k index in differentiating MS from other inflammatory and non-inflammatory neurological diseases .,Assess the diagnostic performance of CSF IgG OCBs in differentiating MS from other inflammatory and non-inflammatory neurological diseases .

Summary

To:
 
 1. Compare the diagnostic performance of cerebrospinal fluid kappa index to that of
 cerebrospinal fluid IgG oligoclonal bands in differentiating multiple sclerosis from
 other inflammatory and non-inflammatory neurological diseases .
 
 2. Assess the role of kappa free light chain and oligoclonal bands in predicting disease
 activity (conversion from clinical isolated syndrome to multiple sclerosis)

ICD-10 classifications
Multiple sclerosisProgressive systemic sclerosisSystemic sclerosisSystemic sclerosis, unspecifiedDiffuse sclerosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06372977
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06372977 through Pure Global AI's free database. This phase not specified trial is sponsored by Assiut University and is currently Not yet recruiting. The study focuses on Multiple Sclerosis. Target enrollment is 140 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.